Save the New Tetracycline Omadacycline (Nuzyra) as a Last Resort

January 2019

You'll see a new, once-daily, IV and PO tetracycline antibiotic, omadacycline (Nuzyra, noo-ZYE-rah).

It's approved for community-acquired pneumonia (CAP)...or skin infections, including methicillin-resistant Staph aureus (MRSA).

Evidence suggests omadacycline is non-inferior to moxifloxacin for CAP or linezolid for skin infections. And omadacycline costs about $350/IV dose or $400/oral dose.

Get unlimited access through an Enterprise license

Hospital Pharmacist's Letter includes:

12 issues every year, with brief articles about new meds and hot topics
300+ CE courses, including the popular CE-in-the-Letter
Quick reference drug comparison charts
Access to the entire archive

Learn More

Already a subscriber? Log in

Not sold to individuals

Iron Consider Expanding Use of Intravenous Iron to More Patients
Delirium Limit Antipsychotics to Patients With Delirium Plus Severe Agitation
Liver Disease Take Special Precautions When Patients With Cirrhosis Undergo Surgery
Venous Thromboembolism Avoid Universal VTE Prophylaxis in Medical Patients
MRSA Use Appropriate MRSA Decolonization Strategies
New Drugs Save the New Tetracycline Omadacycline (Nuzyra) as a Last Resort
Diabetes Consider the CV Benefits of Different SGLT2 Inhibitors
Cardiology Be Ready to Handle Non-Statins During Transitions of Care
Asthma Switch Patients Taking Primatene Mist to Albuterol

Save the New Tetracycline Omadacycline (Nuzyra) as a Last Resort

Get unlimited access through an Enterprise license

Table of Contents